{"id":5631,"date":"2026-07-03T10:39:25","date_gmt":"2026-07-03T08:39:25","guid":{"rendered":"https:\/\/cvja.co.za\/journal\/?p=5631"},"modified":"2026-07-03T10:39:25","modified_gmt":"2026-07-03T08:39:25","slug":"cvja-2026-015","status":"publish","type":"post","link":"https:\/\/cvja.co.za\/journal\/cvja-2026-015\/","title":{"rendered":"Evaluation of six-month clinical outcomes of patients with venous thromboembolism treated with apixaban, rivaroxaban, edoxaban or dabigatran"},"content":{"rendered":"    <div id=\"article\">                                                                                                                        \r\n        <div id=\"title-container\">                                                                                                    \r\n        <div id=\"authors-title\">                                                                                                            \r\n        <!--Aurthors under Title-->                                                                                                            \r\n            \r\nAbdulkadir Yilmaz, Dogan Emre Sert, Sinan Sabit Kocabeyoglu, Emrah Uguz, Enis Burak G\u00fcl, Bekir Bo\u011fa\u00e7han Akkaya, Umit Kervan, Zeki Catav\r\n<\/div>        \r\n<\/div>                                                                                                                            \r\n            <div id=\"copyright\">\r\n        <strong>Copyright:<\/strong> Clinics Cardive Publishing (Pty) Ltd. publisher\r\n        of Cardiovascular Journal of Africa.<\/div>\r\n    <div style=\"clear: both;\"><\/div>                                                                                                                                \r\n        <div id=\"article-abstract\">                                                                                                            \r\n            <div id=\"abstract-title\">                                                                                                        \r\n                    Abstract                                                                                                                \r\n                <\/div>                                                                                                                        \r\n                                                                                                                                \r\n            <div id=\"abstract-content\">                                                                                                        \r\n            <!--Content of Abstract Article-->                                                                                                \r\n            <!--<strong>\"Abstract titles\":<\/strong>-->                                                                                        \r\n            <!--<br\/> at the end of each section!!-->                                                                                        \r\n                                                                                                                                                    \r\n\r\n        <strong>Background:<\/strong>                                                                                                    \r\n                                                                                                                                                    \r\nThe advantages of direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) over warfarin and low molecular weight heparin have been demonstrated in many studies in the treatment of patients with acute venous thromboembolism (VTE). However, a single-centre study comparing the effectiveness and safety of oral anticoagulants against each other has not yet been conducted.\r\n<br \/>    \r\n\r\n        <strong>Aim:<\/strong>                                                                                                    \r\n                                                                                                                                                    \r\nThe study aimed to compare the results of the efficacy and safety profiles of direct oral anticoagulants (DOACs). The purpose of this study was to compare the effectiveness and safety profiles of DOACs.\r\n<br \/>\r\n\r\n        <strong>Method:<\/strong>                                                                                                    \r\n                                                                                                                                                    \r\nThe study included 192 patients diagnosed with VTE in Ankara City Hospital between 2019 and 2022. Patients diagnosed with deep vein thrombosis by venous Doppler ultrasonography and those diagnosed with pulmonary embolism by pulmonary computed tomography angiography (CTA) were included in the study. The patients who received regular treatment for six months and came to their controls regularly were analysed. During the six months, control venous Doppler ultrasonography or pulmonary CTA was performed in all patients with symptoms or examination findings suspicious of VTE. Relevant blood values of patients with hepatic or renal dysfunction were observed at the beginning of the treatment. The primary endpoints were recurrent VTE, mortality, and major bleeding events.\r\n<br \/>\r\n                \r\n                <strong>Results:<\/strong>                                                                                                    \r\nThe 192 patients included in the study were divided into four groups, with at least 45 patients in each drug group. There was no significant difference between the groups regarding gender, age, weight, comorbidity, rate of provoked VTE, and kidney and liver function tests. 90.6% of the patients had isolated deep venous thrombosis. There was a provoking reason in 49.5%. Obesity and immobilisation were the most frequent provoking causes. During the six-month treatment period, recurrent VTE was observed in three patients, major bleeding in two patients, and death in four patients. Non-major bleeding was seen in 40 patients. There was no significant difference between the four drug groups regarding efficacy and safety.\r\n<br \/>\r\n                                                                                                                                                                                                                                                                        \r\n                                                                                                                                                \r\n        <strong>Conclusion:<\/strong>                                                                                                    \r\n                                                                                                                                                    \r\nOur study is essential in comparing the efficacy and safety of four direct oral anticoagulant drugs. Our findings supported that dabigatran, apixaban, edoxaban, and rivaroxaban treatments can be used safely and effectively in the treatment of acute VTE. While high efficacy was achieved with all drugs, a low rate of side effects was observed.\r\n<br \/>    \r\n                                                                                                        \r\n\r\n                                                                                                                                                \r\n            <\/div>                                                                                                                            \r\n        <\/div>                                                                                                                                    \r\n                                                                                                                                        \r\n                                                                                                                                                \r\n        <div id=\"keywords\">                                                                                                                    \r\n                                                                                                                                            \r\n            <strong>Keywords:<\/strong>                                                                                                        \r\n                                                                                                                                            \r\n            <strong>deep vein thrombosis, direct oral anticoagulants, apixaban, rivaroxaban, dabigatran, edoxaban<\/strong>                                                                                                                                                                                                                    \r\n                                                                                                                                                \r\n        <\/div>                                                                                                                                    \r\n                                                                                                                                                \r\n    <div id=\"publish-info\">                                                                                                                    \r\n                                                                                                                                \r\n    <strong>Submitted:<\/strong> October 19, 2025; <!--Month day, year; -->    \r\n    <strong>Accepted:<\/strong> March 5, 2026; <!--Month day, year; -->                                                                            \r\n    <strong>Published:<\/strong> July 3, 2026<!--Month day, year; -->                                                                                                                            <br \/>                                                            \r\n        <em>Cardiovasc J Afr 2025; <b>37<\/b>: 253-258<!--pg no. till pg no. \"eg. 4-7\"--><\/em>\r\n        <br \/><strong>Volume 37, Issue 3<\/strong> <br \/>                                                                            \r\n        <\/div>                                                                                                                            \r\n                                                                                                                                        \r\n    <div id=\"DOI\">                                                                                                                    \r\n            DOI Citation Reference: dx.doi.org\/10.5830\/CVJA-2026-015<!--DOI number-->                                                                \r\n        <\/div>                                                                                                                            \r\n                \r\n                <div id=\"author-affiliation\">                                                                                                \r\n\r\n\r\n<strong>Ankara Bilkent City Hospital, Department of Cardiovascular Surgery, Ankara, Turkey\r\n\r\n<\/strong>    <br \/>                                                                            \r\nAbdulkadir Yilmaz<br \/>\r\nDogan Emre Sert<br \/>\r\nSinan Sabit Kocabeyoglu<br \/>\r\nEnis Burak G\u00fcl<br \/>\r\nBekir Bo\u011fa\u00e7han Akkaya<br \/>\r\nUmit Kervan\r\n<br \/><br \/>   \r\n\r\n<strong>Yildirim Beyazit University Faculty of Medicine, Department of Cardiovascular Surgery, Ankara, Turkey\r\n\r\n<\/strong>    <br \/>                                                                            \r\nEmrah Uguz\r\n<br \/><br \/>   \r\n  \r\n\r\n                [soshsc hide=\"logged\"]\r\n                <strong>You need to be <a style=\"color: #c80c44;\" href=\"https:\/\/cvja.co.za\/journal\/member-login\/\" target=\"_blank\" rel=\"noopener\">logged in to view and download<\/a> the full text PDF version. <a style=\"color: #c80c44;\" href=\"https:\/\/cvja.co.za\/journal\/register\/\" target=\"_blank\" rel=\"noopener\">Register for a free account?<\/a><\/strong> <br \/><br \/>[\/soshsc]\r\n                \r\n                \r\n                \r\n                <\/div>\r\n    \r\n<\/div>","protected":false},"excerpt":{"rendered":"<p>The advantages of direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) over warfarin and low molecular weight heparin have been demonstrated in many studies in the treatment of patients with acute venous thromboembolism (VTE). However, a single-centre study comparing the effectiveness and safety of oral anticoagulants against each other has not yet been conducted.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[44,111],"tags":[],"class_list":["post-5631","post","type-post","status-publish","format-standard","hentry","category-cardiovascular-topics","category-volume-37-issue-3"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Evaluation of six-month clinical outcomes of patients with venous thromboembolism treated with apixaban, rivaroxaban, edoxaban or dabigatran - Cardiovascular Journal of Africa<\/title>\n<meta name=\"description\" content=\"The advantages of direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) over warfarin and low molecular weight heparin have been demonstrated in many studies in the treatment of patients with acute venous thromboembolism (VTE). However, a single-centre study comparing the effectiveness and safety of oral anticoagulants against each other has not yet been conducted.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cvja.co.za\/journal\/cvja-2026-015\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaluation of six-month clinical outcomes of patients with venous thromboembolism treated with apixaban, rivaroxaban, edoxaban or dabigatran - Cardiovascular Journal of Africa\" \/>\n<meta property=\"og:description\" content=\"The advantages of direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) over warfarin and low molecular weight heparin have been demonstrated in many studies in the treatment of patients with acute venous thromboembolism (VTE). However, a single-centre study comparing the effectiveness and safety of oral anticoagulants against each other has not yet been conducted.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cvja.co.za\/journal\/cvja-2026-015\/\" \/>\n<meta property=\"og:site_name\" content=\"Cardiovascular Journal of Africa\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-03T08:39:25+00:00\" \/>\n<meta name=\"author\" content=\"Jaco Moolman\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jaco Moolman\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cvja.co.za\/journal\/cvja-2026-015\/\",\"url\":\"https:\/\/cvja.co.za\/journal\/cvja-2026-015\/\",\"name\":\"Evaluation of six-month clinical outcomes of patients with venous thromboembolism treated with apixaban, rivaroxaban, edoxaban or dabigatran - Cardiovascular Journal of Africa\",\"isPartOf\":{\"@id\":\"https:\/\/cvja.co.za\/journal\/#website\"},\"datePublished\":\"2026-07-03T08:39:25+00:00\",\"author\":{\"@id\":\"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/6bf8a30a039e93fd8112db707affb920\"},\"description\":\"The advantages of direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) over warfarin and low molecular weight heparin have been demonstrated in many studies in the treatment of patients with acute venous thromboembolism (VTE). However, a single-centre study comparing the effectiveness and safety of oral anticoagulants against each other has not yet been conducted.\",\"breadcrumb\":{\"@id\":\"https:\/\/cvja.co.za\/journal\/cvja-2026-015\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cvja.co.za\/journal\/cvja-2026-015\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cvja.co.za\/journal\/cvja-2026-015\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cvja.co.za\/journal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evaluation of six-month clinical outcomes of patients with venous thromboembolism treated with apixaban, rivaroxaban, edoxaban or dabigatran\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cvja.co.za\/journal\/#website\",\"url\":\"https:\/\/cvja.co.za\/journal\/\",\"name\":\"Cardiovascular Journal of Africa\",\"description\":\"The Cardiovascular Journal of Africa is a peer-reviewed medical journal publishing leading research in cardiovascular health across Africa since 1990\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cvja.co.za\/journal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/6bf8a30a039e93fd8112db707affb920\",\"name\":\"Jaco Moolman\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/454c6719ed785bfd40e036ca3c3ac3347c56b4a99902df8beb62d882b1e6967f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/454c6719ed785bfd40e036ca3c3ac3347c56b4a99902df8beb62d882b1e6967f?s=96&d=mm&r=g\",\"caption\":\"Jaco Moolman\"},\"url\":\"https:\/\/cvja.co.za\/journal\/author\/jacodesignconnection-co-za\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaluation of six-month clinical outcomes of patients with venous thromboembolism treated with apixaban, rivaroxaban, edoxaban or dabigatran - Cardiovascular Journal of Africa","description":"The advantages of direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) over warfarin and low molecular weight heparin have been demonstrated in many studies in the treatment of patients with acute venous thromboembolism (VTE). However, a single-centre study comparing the effectiveness and safety of oral anticoagulants against each other has not yet been conducted.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cvja.co.za\/journal\/cvja-2026-015\/","og_locale":"en_US","og_type":"article","og_title":"Evaluation of six-month clinical outcomes of patients with venous thromboembolism treated with apixaban, rivaroxaban, edoxaban or dabigatran - Cardiovascular Journal of Africa","og_description":"The advantages of direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) over warfarin and low molecular weight heparin have been demonstrated in many studies in the treatment of patients with acute venous thromboembolism (VTE). However, a single-centre study comparing the effectiveness and safety of oral anticoagulants against each other has not yet been conducted.","og_url":"https:\/\/cvja.co.za\/journal\/cvja-2026-015\/","og_site_name":"Cardiovascular Journal of Africa","article_published_time":"2026-07-03T08:39:25+00:00","author":"Jaco Moolman","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Jaco Moolman","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cvja.co.za\/journal\/cvja-2026-015\/","url":"https:\/\/cvja.co.za\/journal\/cvja-2026-015\/","name":"Evaluation of six-month clinical outcomes of patients with venous thromboembolism treated with apixaban, rivaroxaban, edoxaban or dabigatran - Cardiovascular Journal of Africa","isPartOf":{"@id":"https:\/\/cvja.co.za\/journal\/#website"},"datePublished":"2026-07-03T08:39:25+00:00","author":{"@id":"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/6bf8a30a039e93fd8112db707affb920"},"description":"The advantages of direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) over warfarin and low molecular weight heparin have been demonstrated in many studies in the treatment of patients with acute venous thromboembolism (VTE). However, a single-centre study comparing the effectiveness and safety of oral anticoagulants against each other has not yet been conducted.","breadcrumb":{"@id":"https:\/\/cvja.co.za\/journal\/cvja-2026-015\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cvja.co.za\/journal\/cvja-2026-015\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cvja.co.za\/journal\/cvja-2026-015\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cvja.co.za\/journal\/"},{"@type":"ListItem","position":2,"name":"Evaluation of six-month clinical outcomes of patients with venous thromboembolism treated with apixaban, rivaroxaban, edoxaban or dabigatran"}]},{"@type":"WebSite","@id":"https:\/\/cvja.co.za\/journal\/#website","url":"https:\/\/cvja.co.za\/journal\/","name":"Cardiovascular Journal of Africa","description":"The Cardiovascular Journal of Africa is a peer-reviewed medical journal publishing leading research in cardiovascular health across Africa since 1990","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cvja.co.za\/journal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/6bf8a30a039e93fd8112db707affb920","name":"Jaco Moolman","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/454c6719ed785bfd40e036ca3c3ac3347c56b4a99902df8beb62d882b1e6967f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/454c6719ed785bfd40e036ca3c3ac3347c56b4a99902df8beb62d882b1e6967f?s=96&d=mm&r=g","caption":"Jaco Moolman"},"url":"https:\/\/cvja.co.za\/journal\/author\/jacodesignconnection-co-za\/"}]}},"_links":{"self":[{"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/posts\/5631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/comments?post=5631"}],"version-history":[{"count":1,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/posts\/5631\/revisions"}],"predecessor-version":[{"id":5633,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/posts\/5631\/revisions\/5633"}],"wp:attachment":[{"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/media?parent=5631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/categories?post=5631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/tags?post=5631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}